IE
CBIO

Israel Englander’s Crescent Biopharma CBIO Stock Holding History

Israel Englander’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-454
Closed -$57K – 6315
2023
Q1 		$57K Buy
454
+354
+354% +$79.7K ﹤0.01% 5580
2022
Q4 		$30K Buy
+100
New +$14.7K ﹤0.01% 5937

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Israel Englander's CBIO Position: Q2 2026 in Review

Israel Englander increased its Crescent Biopharma (CBIO) stake by 25% in Q2 2026, buying an estimated $1.57M and bringing the position to 403,859 shares worth $7.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2642.

Israel Englander first reported a position in CBIO in Q2 2014 and has held it in 36 quarters since. The position peaked at $15.4M in Q2 2017. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Israel Englander held 403,859 shares of Crescent Biopharma worth $7.27M as of Q2 2026.
  • Israel Englander bought 80,306 Crescent Biopharma shares in Q2 2026, an estimated $1.57M.
  • Crescent Biopharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2642 holding.
  • Israel Englander first reported a position in Crescent Biopharma in Q2 2014 and has held it in 36 quarters since.
  • Israel Englander's Crescent Biopharma position peaked at $15.4M in Q2 2017.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.